Cost-effectiveness analysis has to consider all available evidence when informing inputs.

Indeed, to further support our position that the health economic model is flawed and is driven by bias toward high rVE estimates, the vaccine effectiveness used for 18–65 year old (26.8%) has been applied to those aged 9–18 years, yet the Boikos study referred to in their model reports only 18.8% for 4–17 year olds, and this did not reach statistical significance.

also in 111,027 other papers